Hikma Pharmaceuticals Executive and Leadership Team

Ala'a Habboub, the Chief Financial Officer (Jordan) at Hikma Pharmaceuticals, manages all fiscal operations within the regional manufacturing hub. Overseeing capital allocation and budgetary compliance, the Chief Financial Officer (Jordan) ensures that local production facilities maintain optimal cost-efficiency while meeting international quality standards. This leadership role involves rigorous financial reporting and risk assessment to support the broader multinational pharmaceutical strategy. By streamlining procurement processes and optimizing supply chain expenditures, Ala'a Habboub directly impacts the profitability of the generic product portfolio. The Chief Financial Officer (Jordan) collaborates with global leadership to align regional financial performance with the overarching corporate objectives of the organization. Through precise fiscal management, Habboub secures the necessary resources for continued investment in advanced pharmaceutical manufacturing technologies, ultimately driving sustainable growth across the Middle Eastern market and reinforcing the company's competitive position in the global healthcare sector.

Areb Kurdi, the Acting Chief Financial Officer at Hikma Pharmaceuticals, manages the global financial strategy and corporate fiscal health of the multinational organization. Overseeing treasury functions, investor relations, and financial planning, the Acting Chief Financial Officer ensures transparency and accuracy in all reporting cycles. This leadership role involves close collaboration with the Board to evaluate long-term financial performance and capital structure. By implementing robust financial controls and risk management frameworks, Areb Kurdi supports the company's ability to invest in new in-licensed pharmaceutical products. The Acting Chief Financial Officer monitors global market trends to adjust fiscal policies, ensuring the company remains agile in a competitive industry. Through disciplined oversight of corporate assets, Kurdi maintains the financial stability required for international expansion. This strategic focus on fiscal integrity allows the organization to pursue growth opportunities while delivering consistent value to stakeholders, ultimately securing the long-term viability of the pharmaceutical manufacturing business model.

Tareq Darwazeh, the Chief Operating Officer (MENA Region) at Hikma Pharmaceuticals, directs all manufacturing and distribution activities across the Middle East and North Africa. Overseeing complex supply chains and regional production schedules, the Chief Operating Officer (MENA Region) ensures the consistent availability of branded and non-branded generic products. This leadership role requires constant coordination with regulatory bodies to maintain compliance with regional health standards. By optimizing operational workflows and enhancing manufacturing throughput, Tareq Darwazeh directly supports the company's mission to provide affordable healthcare solutions. The Chief Operating Officer (MENA Region) manages large-scale logistics networks to facilitate efficient product delivery to diverse healthcare providers. Through strategic oversight of regional facilities, Darwazeh drives operational excellence and maintains high quality control benchmarks. This focus on efficiency allows the organization to scale production capabilities effectively, meeting the rising demand for essential medicines while strengthening the market presence of the company throughout the entire MENA region.

Bassam Kanaan, the Executive VP, Corporate Development Mergers & Acquisitions at Hikma Pharmaceuticals, architects the company's inorganic growth strategy through strategic partnerships and business acquisitions. Overseeing the identification and evaluation of potential targets, the Executive VP, Corporate Development Mergers & Acquisitions ensures that all new ventures align with the core mission of expanding the portfolio of branded and generic products. This leadership role involves complex negotiations and due diligence to integrate new assets into the existing multinational framework. By securing key in-licensing agreements, Bassam Kanaan directly enhances the company's market reach and therapeutic offerings. The Executive VP, Corporate Development Mergers & Acquisitions collaborates with the C-suite to assess the long-term value of potential acquisitions, ensuring they support the overall corporate strategy. Through proactive market analysis, Kanaan identifies emerging opportunities that strengthen the company's position in the global pharmaceutical industry, ultimately driving innovation and long-term value creation for the organization.

Chawki Sabri, the Finnance at Hikma Pharmaceuticals, directs specialized financial analysis and accounting functions to support the manufacturing of generic pharmaceutical products. Overseeing internal audits and cost accounting, the Finnance ensures that production expenses align with budgetary targets. This leadership role involves analyzing the financial impact of manufacturing variances and identifying opportunities for cost reduction across the supply chain. By providing detailed financial insights, Chawki Sabri enables the executive team to make informed decisions regarding product pricing and resource allocation. The Finnance collaborates with operational managers to improve the efficiency of the manufacturing process, directly contributing to the company's bottom line. Through meticulous tracking of financial data, Sabri maintains the accuracy of corporate records and supports compliance with international accounting standards. This focus on financial precision allows the organization to optimize its manufacturing operations, ensuring the continued delivery of high-quality, affordable medicines to patients worldwide while maintaining a strong competitive edge.